A study led by researchers at Queen Mary University of London found two new common genetic variants in 40,000 individuals which significantly affected the degree to which bad cholesterol was lowered during statin treatment. A follow up study of a further 22,318 individuals confirmed the findings. One of the identified genetic variants was shown to enhance statin response. In contrast, the second variant, thought to have a role in the uptake of statins by the liver, decreased the effects of the drug. Via Science Daily. Posted November 3, 2014.
